First Time Loading...

Takeda Pharmaceutical Co Ltd
TSE:4502

Watchlist Manager
Takeda Pharmaceutical Co Ltd Logo
Takeda Pharmaceutical Co Ltd
TSE:4502
Watchlist
Price: 4 089 JPY 0.79%
Updated: Apr 18, 2024

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Takeda Pharmaceutical Co Ltd

Revenue
4.2T JPY
Cost of Revenue
-1.4T JPY
Gross Profit
2.8T JPY
Operating Expenses
-2.4T JPY
Operating Income
464.9B JPY
Other Expenses
-286.7B JPY
Net Income
178.2B JPY

Margins Comparison
Takeda Pharmaceutical Co Ltd Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
JP
Takeda Pharmaceutical Co Ltd
TSE:4502
6.4T JPY
68%
11%
4%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-3%
-83%
-79%
US
Eli Lilly and Co
NYSE:LLY
712.8B USD
79%
30%
15%
DK
Novo Nordisk A/S
CSE:NOVO B
3.9T DKK
85%
45%
36%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
US
Johnson & Johnson
NYSE:JNJ
348.5B USD
69%
28%
41%
US
Merck & Co Inc
NYSE:MRK
317.4B USD
74%
7%
1%
UK
AstraZeneca PLC
LSE:AZN
170.1B GBP
82%
19%
13%
CH
Roche Holding AG
SIX:ROG
176B CHF
74%
33%
20%
CH
Novartis AG
SIX:NOVN
173B CHF
74%
27%
32%
US
Pfizer Inc
NYSE:PFE
143.5B USD
70%
22%
4%
Country JP
Market Cap 6.4T JPY
Gross Margin
68%
Operating Margin
11%
Net Margin
4%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Operating Margin
-83%
Net Margin
-79%
Country US
Market Cap 712.8B USD
Gross Margin
79%
Operating Margin
30%
Net Margin
15%
Country DK
Market Cap 3.9T DKK
Gross Margin
85%
Operating Margin
45%
Net Margin
36%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Operating Margin
3%
Net Margin
-4%
Country US
Market Cap 348.5B USD
Gross Margin
69%
Operating Margin
28%
Net Margin
41%
Country US
Market Cap 317.4B USD
Gross Margin
74%
Operating Margin
7%
Net Margin
1%
Country UK
Market Cap 170.1B GBP
Gross Margin
82%
Operating Margin
19%
Net Margin
13%
Country CH
Market Cap 176B CHF
Gross Margin
74%
Operating Margin
33%
Net Margin
20%
Country CH
Market Cap 173B CHF
Gross Margin
74%
Operating Margin
27%
Net Margin
32%
Country US
Market Cap 143.5B USD
Gross Margin
70%
Operating Margin
22%
Net Margin
4%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Takeda Pharmaceutical Co Ltd Competitors

Country Company Market Cap ROE ROA ROCE ROIC
JP
Takeda Pharmaceutical Co Ltd
TSE:4502
6.4T JPY
3%
1%
4%
4%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-441%
-47%
-108%
-64%
US
Eli Lilly and Co
NYSE:LLY
712.8B USD
49%
9%
30%
16%
DK
Novo Nordisk A/S
CSE:NOVO B
3.9T DKK
88%
30%
79%
36%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
348.5B USD
49%
21%
19%
16%
US
Merck & Co Inc
NYSE:MRK
317.4B USD
1%
0%
5%
1%
UK
AstraZeneca PLC
LSE:AZN
170.1B GBP
16%
6%
13%
11%
CH
Roche Holding AG
SIX:ROG
176B CHF
40%
13%
30%
23%
CH
Novartis AG
SIX:NOVN
173B CHF
28%
14%
16%
14%
US
Pfizer Inc
NYSE:PFE
143.5B USD
2%
1%
8%
14%
Country JP
Market Cap 6.4T JPY
ROE
3%
ROA
1%
ROCE
4%
ROIC
4%
Country JP
Market Cap 776 550.9T JPY
ROE
-441%
ROA
-47%
ROCE
-108%
ROIC
-64%
Country US
Market Cap 712.8B USD
ROE
49%
ROA
9%
ROCE
30%
ROIC
16%
Country DK
Market Cap 3.9T DKK
ROE
88%
ROA
30%
ROCE
79%
ROIC
36%
Country UK
Market Cap 440.4B GBP
ROE
-4%
ROA
-2%
ROCE
2%
ROIC
2%
Country US
Market Cap 348.5B USD
ROE
49%
ROA
21%
ROCE
19%
ROIC
16%
Country US
Market Cap 317.4B USD
ROE
1%
ROA
0%
ROCE
5%
ROIC
1%
Country UK
Market Cap 170.1B GBP
ROE
16%
ROA
6%
ROCE
13%
ROIC
11%
Country CH
Market Cap 176B CHF
ROE
40%
ROA
13%
ROCE
30%
ROIC
23%
Country CH
Market Cap 173B CHF
ROE
28%
ROA
14%
ROCE
16%
ROIC
14%
Country US
Market Cap 143.5B USD
ROE
2%
ROA
1%
ROCE
8%
ROIC
14%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More